Profit companies

MAPS appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors

  • Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access
  • Appointment Brings Significant Pharma Leadership Experience to MAPS PBC Board of Directors
  • MDMA-assisted therapy, a new treatment for PTSD with FDA Breakthrough Therapy designation, is on track for an NDA submission in 2023 pending confirmatory Phase 3 trial results

SAN JOSE, CA., June 7, 2022 /PRNewswire/ — MAPS Public Benefit Company (MAPS PBC) today announced the appointment of Jeff Georges and Dan GrosmanPh.D., to serve on its board of directors, beginning June 2, 2022. The non-profit association Multidisciplinary Association for Psychedelic Studies (MAPS) The Board of Directors is responsible for appointing MAPS PBC Board members, an important feature of the public interest model.

“Jeff and Dan have world-class backgrounds and extensive experience that will help prepare us to successfully launch and commercialize MAPS’ breakthrough therapy for PTSD. We are delighted to welcome them to our team, who will continue to propel us towards the realization of our mission.” Amy EmersonCEO, PBC CARDS

Jeff Georges brings more than two decades of experience in global healthcare and corporate leadership across North America, Europe, and emerging markets. He is currently a managing partner of Maytal Capital, a healthcare-focused private equity and venture capital firm which he founded in 2017, and a partner of Bridge Builders Collaborative, a startup-focused venture capital firm. on mental health. He previously served as Global CEO of Sandoz and Alcon, within the Novartis Group, where he served on the Executive Committee from 2008 to 2016. George sits on several boards, including listed biopharmaceutical and medical device companies on the stock market and privately. companies, as well as for five non-profit organizations. He holds an MBA from Harvard Business Schoola mastery of Johns Hopkins Universityand a BA of Carleton College.

“I am honored to join the MAPS PBC Board of Directors and have the opportunity to work with the amazing team at MAPS PBC to help bring this life-changing medicine to patients suffering from PTSD. I look forward to to use my experience to advance MAPS PBC’s mission is to catalyze healing and wellness through the development of first-rate drugs for psychedelic-assisted therapies.” Jeff GeorgesBoard Member, MAPS PBC.

Dan Grosman is Managing Director and Senior Partner of Boston Consulting Group (BCG), one of the world’s leading management consulting firms. He has nearly 20 years of experience in the healthcare practice area of ​​BCG, working with leading biopharmaceutical and medical technology companies on issues of corporate strategy, pipeline development and commercialization of innovation on a global scale. His experience spans therapeutic areas, with significant depth in major areas of neuroscience. He served as the Learning and Development Manager for BCG in North America and is responsible for BCG’s portfolio of proprietary data and software tools for healthcare practice. Grossman is also treasurer and member of the executive committee of the board of directors of the Opéra Lyrique de Chicago. He holds a doctorate. of princeton university and a BA of Harvard College.

“MAPS PBC is an organization on the cusp of bringing breakthrough innovation to market. I am grateful to join the Board at this inflection point and have the opportunity to work with the Board and the team direction to advance psychedelic treatments and improve the lives of millions of people suffering from the most intractable and harrowing mental health issues, such as PTSD.” Dan GrosmanBoard Member, MAPS PBC.

MAPS and MAPS PBC plan to submit a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA-assisted therapy for PTSD in 2023. MAPS intends to seek priority review, which reduces the target review time for a drug from ten months to six. Recent reports from the National Center for PTSD estimate that 12 million Americans are currently living with PTSD, an increase of nearly 50% over previous estimates, highlighting the substantial existing need for new treatment options. The appointment of these seasoned leaders brings significant business, market access and organizational development expertise to the MAPS PBC Board and organization to support accelerating the potential for patient access to this breakthrough therapy. .

Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the prudent use of psychedelics and marijuana. . MAPS sponsors the world’s most advanced psychedelic therapy research: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since the inception of MAPS, donors and philanthropic donors have given more than $130 million for research and education on psychedelics and marijuana. MAPS won both the Guidestar Platinum Transparency Seal and one 4-star rating from Charity Navigator.

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and wellness through psychedelic drug development, therapist training programs, marketing, and patient access to prescription psychedelics while prioritizing public benefit rather than profit. Founded in 2014, MAPS PBC is a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization. MAPS PBC is the parent company of MAPS EU, established to organize and administer clinical trials of MDMA-assisted therapy for PTSD in the UK and EU.

Betty AldworthDirector of Communications, MAPS or [email protected]
831-429-6362 ext. 303

SOURCE Multidisciplinary Association for Psychedelic Studies